Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients-Reference-Cited by-同舟云学术

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Published:2020-03-09 Issue:5 Volume:87 Page:688-699
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol

Author:

Alping Peter¹²^ORCID,Askling Johan²,Burman Joachim³,Fink Katharina¹⁴,Fogdell‐Hahn Anna¹,Gunnarsson Martin⁵,Hillert Jan¹⁶,Langer‐Gould Annette⁷,Lycke Jan⁸,Nilsson Petra⁹,Salzer Jonatan¹⁰,Svenningsson Anders¹¹,Vrethem Magnus¹²,Olsson Tomas¹⁴,Piehl Fredrik¹⁴,Frisell Thomas²^ORCID

Affiliation:

1. Department of Clinical NeuroscienceKarolinska Institute Stockholm Sweden

2. Clinical Epidemiology Division, Department of Medicine SolnaKarolinska Institute Stockholm Sweden

3. Department of NeuroscienceUppsala University Uppsala Sweden

4. Academic Specialist CenterStockholm Health Services Stockholm Sweden

5. Department of Neurology, Faculty of Medicine and HealthÖrebro University Örebro Sweden

6. Department of NeurologyKarolinska University Hospital Stockholm Sweden

7. Clinical and Translational NeuroscienceSouthern California Permanente Medical Group, Kaiser Permanente Pasadena CA

8. Department of Clinical Neuroscience and RehabilitationUniversity of Gothenburg Gothenburg Sweden

9. Department of Clinical Sciences/NeurologyLund University Lund Sweden

10. Department of Pharmacology and Clinical NeuroscienceUmeå University Umeå Sweden

11. Department of Clinical SciencesKarolinska Institute, Danderyd Hospital Stockholm Sweden

12. Department of Clinical and Experimental MedicineLinköping University Linköping Sweden

Funder

Patient-Centered Outcomes Research Institute

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.25701

Reference46 articles.

1. Multiple sclerosis

2. A changing treatment landscape for multiple sclerosis: challenges and opportunities

3. HillertJ.Neuroreg.Se— Swedish Multiple Sclerosis Register. Available at:http://www.neuroreg.se/. Accessed August 1 2019.

4. Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

5. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dermatological Neoplastic Diseases Complicating Treatment with Monoclonal Antibodies for Multiple Sclerosis;Journal of Clinical Medicine;2024-08-29

2. Data-driven risk/benefit estimator for multiple sclerosis therapies;2024-08-17

3. MS treatment de-escalation: review and commentary;Journal of Neurology;2024-08-02

4. Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy;Drug Design, Development and Therapy;2024-07

5. COMBAT‐MS: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab;Annals of Neurology;2024-06-25